Overview

Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

Status:
Withdrawn
Trial end date:
2019-02-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if rifaximin reduces serum trimethylamine-N-oxide (TMAO) levels in patients with end-stage renal disease.
Phase:
Early Phase 1
Details
Lead Sponsor:
Jason Stubbs, MD
Collaborator:
American Heart Association
Treatments:
Rifamycins
Rifaximin